DGIdb - LETROZOLE Drug Record

LETROZOLE chembl:CHEMBL1444 ApprovedAntineoplastic

Alternate Names:

LETROZOLE
FEMARA
CGS-20267
FEM345
FEMARA®
LETROZOL
rxcui:72965
drugbank:01006
chemidplus:112809-51-5
chembl:CHEMBL1444
pubchem.compound:3902

Drug Info:

Year of Approval	1997
Drug Class	antineoplastic agents
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(8 More Sources)

Publications:

Ferlin MG et al., 2013, Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors., J Med Chem
Oesterreich S et al., 2015, Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover., Breast Cancer Res Treat
Santa-Maria CA et al., 2016, Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy., Clin Cancer Res
Wang L et al., 2010, Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors., Cancer Res
Long et al., 2004, Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model., J. Natl. Cancer Inst.
Murphy, 1998, Molecular Action and Clinical Relevance of Aromatase Inhibitors., Oncologist
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Ebert et al., [Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis]., Zentralbl Gynakol
Finn et al., 2015, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study., Lancet Oncol.
Johnston et al., 2009, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer., J. Clin. Oncol.
Gao et al., 2015, Does CDKN2A loss predict palbociclib benefit?, Curr Oncol
Mayer et al., 2017, A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer., Clin. Cancer Res.
Borrie AE et al., 2018, Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer., Breast Cancer Res Treat
Desta Z et al., 2011, Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age., Clin Pharmacol Ther
Kitagawa K et al., 1999, The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP., Biochem Biophys Res Commun
Oscarson M et al., 1998, Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase., FEBS Lett
Wang H et al., 2011, Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes., Pharmacogenomics
Tanii H et al., 2011, Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women., Eur J Clin Pharmacol
Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
Hirose T et al., 2010, Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer., Oncol Rep
Djordjevic N et al., 2010, In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population., Eur J Clin Pharmacol
Tan L et al., 2010, The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients., Clin Neurol Neurosurg
Ishii Y et al., 2010, Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?, Cancer Chemother Pharmacol
Murai K et al., 2009, Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes., Xenobiotica
Kong SY et al., 2009, Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer., Pharmacogenomics
di Iulio J et al., 2009, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function., Pharmacogenet Genomics
Arab-Alameddine M et al., 2009, Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals., Clin Pharmacol Ther
Endo T et al., 2008, Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine., Pharmacogenet Genomics
Fujita K et al., 2008, CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1., Cancer Sci
Kaida Y et al., 2008, The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer., Clin Pharmacol Ther
Peamkrasatam S et al., 2006, In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais., Drug Metab Pharmacokinet
Audrain-McGovern J et al., 2007, The role of CYP2A6 in the emergence of nicotine dependence in adolescents., Pediatrics
Benowitz NL et al., 2006, CYP2A6 genotype and the metabolism and disposition kinetics of nicotine., Clin Pharmacol Ther
Nakajima M et al., 2006, Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations., Clin Pharmacol Ther
Nurfadhlina M et al., 2006, CYP2A6 polymorphisms in Malays, Chinese and Indians., Xenobiotica
Minematsu N et al., 2006, Limitation of cigarette consumption by CYP2A64, 7 and *9 polymorphisms., Eur Respir J
Malaiyandi V et al., 2006, Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy., Mol Psychiatry
Wang J et al., 2006, 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression., Biochem Biophys Res Commun
Huang S et al., 2005, CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents., Pharmacogenet Genomics
Kimura M et al., 2005, Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans., Drug Metab Dispos
Gambier N et al., 2005, Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort., Pharmacogenomics J
Fukami T et al., 2005, Characterization of novel CYP2A6 polymorphic alleles (CYP2A618 and CYP2A619) that affect enzymatic activity., Drug Metab Dispos
Gyamfi MA et al., 2005, High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana., Eur J Clin Pharmacol
Fukami T et al., 2004, A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo., Clin Pharmacol Ther
Schoedel KA et al., 2004, Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians., Pharmacogenetics
Fujieda M et al., 2004, Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers., Carcinogenesis
Yamanaka H et al., 2004, Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted., Eur J Pharm Sci
Nakajima M et al., 2004, Novel human CYP2A6 alleles confound gene deletion analysis., FEBS Lett
Iwahashi K et al., 2004, Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior., Neuropsychobiology
Yoshida R et al., 2003, Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro., Clin Pharmacol Ther
Smith IE et al., 2003, Aromatase inhibitors in breast cancer., N Engl J Med
Ando M et al., 2003, Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults., J Epidemiol
Oscarson M et al., 2002, Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity., Hum Mutat
Ariyoshi N et al., 2002, Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers., Cancer Epidemiol Biomarkers Prev
Daigo S et al., 2002, A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur., Pharmacogenetics
Xu C et al., 2002, An in vivo pilot study characterizing the new CYP2A67, 8, and *10 alleles., Biochem Biophys Res Commun
Zhang X et al., 2001, Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population., Nihon Arukoru Yakubutsu Igakkai Zasshi
Paschke T et al., 2001, Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method., Toxicology
Kwon JT et al., 2001, Nicotine metabolism and CYP2A6 allele frequencies in Koreans., Pharmacogenetics
Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun
Tan W et al., 2001, Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population., Int J Cancer
Ariyoshi N et al., 2001, A novel single nucleotide polymorphism altering stability and activity of CYP2a6., Biochem Biophys Res Commun
Nakajima M et al., 2001, Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans., Clin Pharmacol Ther
Rao Y et al., 2000, Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking., Mol Pharmacol
Oscarson M et al., 1999, Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism., FEBS Lett
Mitropoulou et al., 2003, Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells., Int. J. Cancer
Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.
Gala K et al., 2018, KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function., Oncogene

LETROZOLE CYP2A6

Interaction Score: 9.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30094551 21975350 10448083 9827545 21521021 21494765 20860463 20596643 20155256 20089352 19921195 19845430 19604090 19238117 19225447 18698229 18380793 18212800 17220563 17130279 17112802 16952495 16891249 16452582 16402128 16378601 16272956 15980104 15940289 15900015 15660270 15592323 15475735 15308589 15265511 15225612 14981342 12844137 12802030 12749606 12325023 12223434 12042667 11779172 11725533 11684323 11434509 11394901 11241319 11237731 11180041 10999944 10544257

Sources:
PharmGKB
LETROZOLE KMT2C

Interaction Score: 2.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29755131

Sources:
CIViC
LETROZOLE CYP19A1

Interaction Score: 1.82

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name letrozole ,Femara

Novel drug target Established target

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs:
24025069 26536870 26463708 20048079 15026471 10388095 11752352 14505258

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
LETROZOLE TNFSF11

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LETROZOLE TNFRSF11B

Interaction Score: 0.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LETROZOLE CDKN2A

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26715889

Sources:
CIViC
LETROZOLE MMP2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12569569

Sources:
NCI
LETROZOLE CYP1B1

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18256205

Sources:
NCI
LETROZOLE PGR

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers PharmGKB FDA
LETROZOLE ESR2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26536870

Sources:
PharmGKB
LETROZOLE ESR1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26536870 25524798

Sources:
ClearityFoundationBiomarkers CIViC PharmGKB FDA
LETROZOLE PIK3CA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type no benefit

Indication/Tumor Type estrogen-receptor positive breast cancer

combination therapy Letrozole + BYL719

PMIDs:
27126994

Sources:
JAX-CKB
LETROZOLE ERBB2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Lapatinib + Letrozole

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type sensitive

PMIDs:
19786658

Sources:
JAX-CKB
LETROZOLE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: LETROZOLE
- Version: 01-August-2011
Alternate Names:

LETROZOLE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1997

Publications:
TdgClinicalTrial: LETROZOLE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: LETROZOLE

Version: 14-September-2017

Alternate Names:

C1527 NCI drug code

Drug Info:

Publications:

Mitropoulou et al., 2003, Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells., Int. J. Cancer

Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.

DTC: LETROZOLE
- Version: 02-September-2020
Alternate Names:

CHEMBL1444 ChEMBL Drug ID

Drug Info:

Publications:

Ferlin MG et al., 2013, Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors., J Med Chem

JAX-CKB: Letrozole

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Johnston et al., 2009, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer., J. Clin. Oncol.

Mayer et al., 2017, A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer., Clin. Cancer Res.

PharmGKB: letrozole

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Oesterreich S et al., 2015, Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover., Breast Cancer Res Treat

Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun

Malaiyandi V et al., 2006, Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy., Mol Psychiatry

CIViC: LETROZOLE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Finn et al., 2015, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study., Lancet Oncol.

Gao et al., 2015, Does CDKN2A loss predict palbociclib benefit?, Curr Oncol

Gala K et al., 2018, KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function., Oncogene

TTD: Letrozole
- Version: 2020.06.01
Alternate Names:

D0C1WH TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1444
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1444
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: LETROZOLE
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
FDA: Letrozole
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	letrozole ,Femara
Novel drug target	Established target
Mechanism of Interaction	Cytochrome P450 19A1 inhibitor

Response Type	no benefit
Indication/Tumor Type	estrogen-receptor positive breast cancer
combination therapy	Letrozole + BYL719

combination therapy	Lapatinib + Letrozole
Indication/Tumor Type	Her2-receptor positive breast cancer
Response Type	sensitive

antagonist (inhibitory)
inhibitor (inhibitory)

LETROZOLE Drug Record

LETROZOLE chembl:CHEMBL1444 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29755131

Sources: CIViC

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name letrozole ,Femara Novel drug target Established target Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs: 24025069 26536870 26463708 20048079 15026471 10388095 11752352 14505258

Sources: DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26715889

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12569569

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18256205

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26536870

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26536870 25524798

Sources: ClearityFoundationBiomarkers CIViC PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info: Response Type no benefit Indication/Tumor Type estrogen-receptor positive breast cancer combination therapy Letrozole + BYL719

PMIDs: 27126994

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Lapatinib + Letrozole Indication/Tumor Type Her2-receptor positive breast cancer Response Type sensitive

PMIDs: 19786658

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: LETROZOLE

Alternate Names: LETROZOLE Primary Drug Name

Drug Info: Drug Class antineoplastic agents Year of Approval 1997

Publications:

TdgClinicalTrial: LETROZOLE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small Molecule FDA Approval approved

Publications:

NCI: LETROZOLE

Alternate Names: C1527 NCI drug code

Drug Info:

DTC: LETROZOLE

Alternate Names: CHEMBL1444 ChEMBL Drug ID

Drug Info:

Publications: Ferlin MG et al., 2013, Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors., J Med Chem

JAX-CKB: Letrozole

Alternate Names:

Drug Info:

PharmGKB: letrozole

Alternate Names:

Interaction Types & Directionality:

n/a

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29755131

Sources:
CIViC

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name letrozole ,Femara

Novel drug target Established target

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs:
24025069 26536870 26463708 20048079 15026471 10388095 11752352 14505258

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26715889

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
12569569

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18256205

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
26536870

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26536870 25524798

Sources:
ClearityFoundationBiomarkers CIViC PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type no benefit

Indication/Tumor Type estrogen-receptor positive breast cancer

combination therapy Letrozole + BYL719

PMIDs:
27126994

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Lapatinib + Letrozole

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type sensitive

PMIDs:
19786658

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

LETROZOLE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1997

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C1527 NCI drug code

Alternate Names:

CHEMBL1444 ChEMBL Drug ID

Publications:

Ferlin MG et al., 2013, Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors., J Med Chem

Alternate Names:

D0C1WH TTD Drug ID